Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic ModelingJacqueline G. Gerhart, Robert H. Lurie, Kanecia O. Zimmerman et al.|Clinical Pharmacokinetics|2021Cited by 39
Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With ObesityJacqueline G. Gerhart, Daniel González, Fernando Carreño et al.|Clinical Pharmacology & Therapeutics|2022Cited by 30
Use of <scp>physiologically‐based</scp> pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesityJacqueline G. Gerhart, Daniel González, Fernando Carreño et al.|CPT Pharmacometrics & Systems Pharmacology|2022Cited by 14
Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric PopulationSara Salerno, Daniel González, Fernando Carreño et al.|Drug Metabolism and Disposition|2021Cited by 12
Pharmacokinetics of hERG Channel Blocking Voacangine in Wistar Rats Applying a Validated LC-ESI-MS/MS MethodChristina E. Mair, Judith M. Rollinger, Carolina de Miranda Silva et al.|Planta Medica|2016Cited by 5